Successful Integration of Tuberculosis and HIV Treatment in Rural South Africa: The Sizonq'oba Study

Background:Tuberculosis (TB) is the leading cause of death among HIV-infected patients worldwide. In KwaZulu-Natal, South Africa, 80% of TB patients are HIV coinfected, with high treatment default and mortality rates. Integrating TB and HIV care may be an effective strategy for improving outcomes for both diseases. Methods:Prospective operational research study treating TB/HIV-coinfected patients in rural KwaZulu-Natal with once-daily antiretroviral (ARV) therapy concurrently with TB therapy by home-based, modified directly observed therapy. Patients were followed for 12 months after ARV initiation. Results:Of 119 TB/HIV-coinfected patients enrolled, 67 (56%) were female, mean age was 34.0 years, and median CD4 count was 78.5 cells per cubic millimeter. After 12 months on ARVs, mean CD4 count increase was 211 cells per cubic millimeter, and 88% had an undetectable viral load; 84% completed TB treatment. Thirteen patients (11%) died; 10 (77%) with multidrug-resistant or extensively drug-resistant TB. There were few severe adverse events or immune reconstitution events. Adherence was high with 93% of study visits attended and 99% of ARV doses taken. Conclusions:Integration of TB and HIV treatment in a rural setting using concurrent home-based therapy resulted in excellent adherence and TB and HIV outcomes. This model may result in successful management of both diseases in other rural resource-poor settings.

[1]  J. Tappero,et al.  Mortality in HIV-infected Ugandan adults receiving antiretroviral treatment and survival of their HIV-uninfected children: a prospective cohort study , 2008, The Lancet.

[2]  A. W. Sturm,et al.  Evolution of the extensively drug-resistant F15/LAM4/KZN strain of Mycobacterium tuberculosis in KwaZulu-Natal, South Africa. , 2007, Clinical Infectious Diseases.

[3]  D. Kuritzkes,et al.  Antiretroviral therapy-associated toxicities in the resource-poor world: the challenge of a limited formulary. , 2007, The Journal of infectious diseases.

[4]  S. Basu,et al.  Prevention of nosocomial transmission of extensively drug-resistant tuberculosis in rural South African district hospitals: an epidemiological modelling study , 2007, The Lancet.

[5]  G. Maartens,et al.  Complications of antiretroviral therapy in patients with tuberculosis: drug interactions, toxicity, and immune reconstitution inflammatory syndrome. , 2007, The Journal of infectious diseases.

[6]  K. D. de Cock,et al.  Tuberculosis and HIV infection: the global setting. , 2007, The Journal of infectious diseases.

[7]  E. Nardell,et al.  Tuberculosis infection control in resource-limited settings in the era of expanding HIV care and treatment. , 2007, The Journal of infectious diseases.

[8]  D. Havlir,et al.  Treatment strategies for HIV-infected patients with tuberculosis: ongoing and planned clinical trials. , 2007, The Journal of infectious diseases.

[9]  A. Harries,et al.  Implementation issues in tuberculosis/HIV program collaboration and integration: 3 case studies. , 2007, The Journal of infectious diseases.

[10]  D. Hospenthal,et al.  Infectious complications of open type III tibial fractures among combat casualties. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[11]  S. Akksilp,et al.  Antiretroviral Therapy during Tuberculosis Treatment and Marked Reduction in Death Rate of HIV-Infected Patients, Thailand1 , 2007, Emerging infectious diseases.

[12]  G. Bai,et al.  Worldwide Emergence of Extensively Drug-resistant Tuberculosis , 2007, Emerging infectious diseases.

[13]  A. R. Escombe,et al.  Natural Ventilation for the Prevention of Airborne Contagion , 2007, PLoS medicine.

[14]  W. El-Sadr,et al.  Tuberculosis and HIV–Needed: A New Paradigm for the Control and Management of Linked Epidemics , 2007 .

[15]  S. Khoo,et al.  Administration of efavirenz (600 mg/day) with rifampicin results in highly variable levels but excellent clinical outcomes in patients treated for tuberculosis and HIV. , 2006, The Journal of antimicrobial chemotherapy.

[16]  Neel R Gandhi,et al.  Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa , 2006, The Lancet.

[17]  L. López-Cortés,et al.  Efavirenz trough levels are not associated with virological failure throughout therapy with 800 mg daily and a rifampicin-containing antituberculosis regimen. , 2006, The Journal of antimicrobial chemotherapy.

[18]  C. Dye,et al.  Towards universal access to HIV prevention, treatment, care, and support: the role of tuberculosis/HIV collaboration. , 2006, The Lancet. Infectious diseases.

[19]  L. Myer,et al.  Impact of HIV infection on the epidemiology of tuberculosis in a peri-urban community in South Africa: the need for age-specific interventions. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[20]  J. Sterne,et al.  Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries , 2006, The Lancet.

[21]  L. Myer,et al.  Early mortality among adults accessing a community-based antiretroviral service in South Africa: implications for programme design , 2005, AIDS.

[22]  P. Wright,et al.  Antiretroviral therapy in a thousand patients with AIDS in Haiti. , 2005, The New England journal of medicine.

[23]  A. Vibhagool,et al.  Efavirenz levels and 24-week efficacy in HIV-infected patients with tuberculosis receiving highly active antiretroviral therapy and rifampicin , 2005, AIDS.

[24]  S. Lawn,et al.  Immune reconstitution disease associated with mycobacterial infections in HIV-infected individuals receiving antiretrovirals. , 2005, The Lancet. Infectious diseases.

[25]  W. El-Sadr,et al.  A Pilot Study of Once-Daily Antiretroviral Therapy Integrated With Tuberculosis Directly Observed Therapy in a Resource-Limited Setting , 2004, Journal of acquired immune deficiency syndromes.

[26]  U. Lalloo,et al.  Utility of tuberculosis directly observed therapy programs as sites for access to and provision of antiretroviral therapy in resource-limited countries. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[27]  S. Karim,et al.  Implementing antiretroviral therapy in resource-constrained settings: opportunities and challenges in integrating HIV and tuberculosis care , 2004, AIDS.

[28]  G. Maartens,et al.  Outcomes after two years of providing antiretroviral treatment in Khayelitsha, South Africa , 2004, AIDS.

[29]  E. Delaporte,et al.  Once-a-day highly active antiretroviral therapy in treatment-naive HIV-1-infected adults in Senegal , 2003, AIDS.

[30]  J. Ena,et al.  Once-a-day highly active antiretroviral therapy: a systematic review. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[31]  F. Lampe,et al.  Outcome of HIV-associated tuberculosis in the era of highly active antiretroviral therapy. , 2002, The Journal of infectious diseases.

[32]  M. Chesney,et al.  The consistency of adherence to antiretroviral therapy predicts biologic outcomes for human immunodeficiency virus-infected persons in clinical trials. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[33]  A. Harries,et al.  Tuberculosis case fatality rates in high HIV prevalence populations in sub-Saharan Africa , 2001, AIDS.

[34]  C. Connolly,et al.  Relapse and mortality among HIV-infected and uninfected patients with tuberculosis successfully treated with twice weekly directly observed therapy in rural South Africa. , 1999, AIDS.

[35]  P. Sonnenberg,et al.  Human immunodeficiency virus and the outcome of treatment for new and recurrent pulmonary tuberculosis in African patients. , 1999, American journal of respiratory and critical care medicine.

[36]  Organización Mundial de la Salud,et al.  Towards universal access: scaling up priority HIV/AIDS interventions in the health sector. Progress report 2009 , 2009 .

[37]  Summary TOWARDS UNIVERSAL ACCESS : Scaling up Priority HIV / AIDS Interventions in the Health Sector Progress Report , 2008 .

[38]  Anthony D. Harries,et al.  Treatment of tuberculosis: guidelines for national programmes. Second edition. , 1997 .

[39]  David Satcher,et al.  Guidelines for preventing the transmission of Mycobacterium tuberculosis in health-care facilities, 1994--CDC. Notice of final revisions to the "Guidelines for Preventing the Transmission of Mycobacterium Tuberculosis in health-care facilities, 1994". , 1994, Federal register.